BioSpace News Archive

Agenus Inc. today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024.

Compass Therapeutics, Inc. announced that the Company will participate in the Leerink Partners Global Biopharma Conference in Miami Beach, Florida on Wednesday, March 13, 2024.

MoonLake Immunotherapeutics announced its financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

ZyVersa Therapeutics, Inc. announces that on February 26, 2024, the company generated approximately $2.7 Million from existing investors’ exercise of previously issued warrants.

IRLAB Therapeutics Gothenburg, Sweden, February 29, 2024 - IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present at the event Life Science-dagen in Gothenburg on March 6.

ONWARD Medical N.V. announces it has been awarded Breakthrough Device Designation by the US Food and Drug Administration for the ARC-BCI System, which uses brain-computer interface technology in conjunction with its ARC-IM® Therapy to restore thought-driven lower limb mobility after spinal cord injury.

Pharming Group N.V. confirms it will report its preliminary fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its participation in the Leerink Partners Global Biopharma Conference, taking place on March 11-13, in Miami, Florida, USA.

SN Bioscience Co. Ltd. announced on Feb 27 that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101, a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model.

Embolx Inc. is thrilled to announce that the U.S. Food and Drug Administration has granted clearance for the Soldier® High Flow Microcatheter, advancing localized drug delivery in vascular interventions.